197 results on '"Camiciottoli, Gianna"'
Search Results
2. Pulmonary emphysema and coronary artery calcifications at baseline LDCT and long-term mortality in smokers and former smokers of the ITALUNG screening trial
3. “Adrenaline junkie”: a case report of repeated use of epinephrine
4. Severe Asthma Network Italy Definition of Clinical Remission in Severe Asthma: A Delphi Consensus
5. TRITRIAL: The Impact of Fixed Triple Therapy with Beclometasone/Formoterol/Glycopyrronium on Health Status and Adherence in Chronic Obstructive Pulmonary Disease in an Italian Context of Real Life
6. Severe asthma: One disease and multiple definitions
7. Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life
8. Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)
9. The Severe Asthma Network in Italy: Findings and Perspectives
10. Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry
11. Emphysema Severity Index (ESI): a novel spirometry-derived parameter in patients with COPD
12. TRITRIAL study - TRIple Therapy in Real life: Impact on Adherence and HeaLth status in COPD patients in Italy.
13. The Impact of Extrafine Beclometasone/Formoterol/Glycopyrronium on Sleep disturbance in Chronic Obstructive Pulmonary Disease (COPD) in an Italian Context of Real Life: The TRITRIAL Study.
14. Glottis Closure Influences Tracheal Size Changes in Inspiratory and Expiratory CT in Patients with COPD
15. Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry
16. Spirometric assessment of emphysema presence and severity as measured by quantitative CT and CT-based radiomics in COPD
17. Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy
18. Patients and doctors group meetings: an innovative way to explore severe asthma backstage
19. Do COPD subtypes really exist? COPD heterogeneity and clustering in 10 independent cohorts
20. Lung vascular changes as biomarkers of severity in systemic sclerosis–associated interstitial lung disease
21. “Adrenaline junkie”: a case report of repeated use of epinephrine
22. Lung vascular changes as biomarkers of severity in systemic sclerosis–associated interstitial lung disease.
23. Severe asthma: One disease and multiple definitions
24. Explorative data analysis techniques and unsupervised clustering methods to support clinical assessment of Chronic Obstructive Pulmonary Disease (COPD) phenotypes
25. Agreement between two methods for assessing bioequivalence of inhaled salbutamol
26. Whole-lung densitometry versus visual assessment of emphysema
27. Prevalence and correlates of pulmonary emphysema in smokers and former smokers. A densitometric study of participants in the ITALUNG trial
28. Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life
29. Discriminant Profiles of Volatile Compounds in the Alveolar Air of Patients with Squamous Cell Lung Cancer, Lung Adenocarcinoma or Colon Cancer
30. Lung CT Densitometry in Systemic Sclerosis: Correlation With Lung Function, Exercise Testing, and Quality of Life
31. Mepolizumab Effectiveness and Allergic Status in Real Life
32. Spirometrically Gated High-Resolution CT Findings in COPD: Lung Attenuation vs Lung Function and Dyspnea Severity
33. A “gender phenotype” does really exist in severe asthma
34. Quantitative analysis of pulmonary vasculature in systemic sclerosis at spirometry-gated chest CT
35. Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life
36. Additional file 1: of Spirometric assessment of emphysema presence and severity as measured by quantitative CT and CT-based radiomics in COPD
37. Fog-induced Respiratory Responses Are Attenuated by Nedocromil Sodium in Humans
38. Mepolizumab Effectiveness and Allergic Status in Real Life.
39. The Severe Asthma Network in Italy: Findings and Perspectives
40. Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry
41. Changes in transcutaneous oxygen partial pressure as an index of response to inhaled methacholine in asthmatic patients
42. Clinical features and functional parameters predict the probability of ACO in patients with asthma and COPD
43. Emphysematous and Nonemphysematous Gas Trapping in Chronic Obstructive Pulmonary Disease: Quantitative CT Findings and Pulmonary Function
44. Asthma remission one, none and one-hundred thousand: the relevance of the patient’s view.
45. Asthma-COPD overlap syndrome (ACOS): a comparison between five different classification models
46. Lung densitometry: why, how and when
47. A predictive model for classifying COPD patients according to CT emphysema extent by using functional data and BMI
48. OSACO: an observational study in asthma-COPD overlap syndrome (ACOS)
49. Prevalence of comorbidities according to predominant phenotype and severity of chronic obstructive pulmonary disease
50. Can we consider the“frequent exacerbator”a reliable COPD phenotype?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.